[1] 朱倩,乔国梁,晏建军,等. 可切除肝门部胆管癌预后影响因素分析. 中华肝胆外科杂志,2014,20(9):662-666. [2] Peng C,Li C,Wen T,et al.Left hepatectomy combined with hepatic artery resection for hilar cholangiocarcinoma:A retrospective cohort study.Int J Surg,2016,32:167-173. [3] 刘振国,强永乾. 螺旋CT和MRI对肝内周围型胆管癌诊断价值分析. 实用肝脏病杂志,2016,19(5):591-594. [4] 刘召波,卢实春,李宁,等. 肝门部胆管癌的外科治疗. 中华消化外科杂志,2013,12(3):186-190. [5] Liska V,Treska V,Skalicky T,et al.Evaluation of tumor markers and their impact on prognosis in gallbladder,bile duct and cholangiocellular carcinomas-apilot study. Anticancer Res,2017 37(4):2003. [6] Ebata T,Kosuge T,Hirano S,et al.Proposal to modify the international union against cancer staging system for perihilar cholangiocarcinomas. Br J Surg,2014,101(2):79. [7] Tsai CY,Watanabe N,Ebata T,et al.Right hepatectomy for a detoured left hepatic artery in hilar cholangiocarcinoma-report of a rare but rational resection. World J Surg Oncol,2016,14(1):288-394. [8] Moon A,Chin S,Kim H K,et al.EGFR,COX2,p-AKT expression and PIK3CA mutation in distal extrahepatic bile duct carcinoma. Pathology,2016,48(1):35. [9] Lee SG,Song GW,Hwang S,et al.Surgical treatment of hilar cholangiocarcinoma in the new era:the Asan experience.J Hepatobiliary Pancreat Sci,2010,17(4):476-489. [10] Noji T,Tsuchikawa T,Okamura K,et al.Concomitant hepatic artery resection for advanced perihilar cholangiocarcinoma:a case-control study with propensity score matching. J Hepatobiliary Pancreat Sci,2016,23(7):442-448. [11] Xiong JJ,Nunes QM,Huang W,et al.Preoperative biliary drainage in patients with hilar cholangiocarcinoma undergoing major hepatectomy. World J Gastroenterol,2013,19(46):8731-8739. [12] Machado MA,Makdissi FF,Surjan RC.Right trisectionectomy with principle en bloc portal vein resection for right-sided hilar cholangiocarcinoma:no-touch technique.Ann Surg Oncol,2012,19(4):1324-1325. [13] 张辉,王孟龙. 单中心56例肝门部胆管癌的外科治疗. 中华肝胆外科杂志,2017,23(1):16-19. [14] Kuriyama N,Isaji S,Tanemura A,et al.Transhepatic hilar approach for perihilar cholangiocarcinoma:significance of early judgment of resectability and safe vascular reconstruction.J Gastrointest Surg,2017,21(3):590-599. [15] Seehofer D,Neuhaus P.Strategies to optimise roresection for hilar cholangiocarcinoma.Zentralbl Chir,2016,141(4):397-404. [16] Oba A,Takahashi S,Kato Y,et al.Usefulness of resection for hepatocellular carcinoma with macroscopic bile duct tumor thrombus. Anticancer Res,2014,34(8):4367-4372. [17] 曹光材,白江江,戴阿利. 胆管癌组织紧密连结蛋白18、丝氨酸蛋白酶抑制剂和p53蛋白表达及其临床意义. 实用肝脏病杂志,2017,20(3):312-315. [18] Yeh TS,Wang F,Chen TC,et al.Expression profile of microRNA-200 family in hepatocellular carcinoma with bile duct tumor thrombus. Ann Surg,2014,259(2):346-354. [19] Kasai Y,Hatano E,Seo S,et al.Hepatocellular carcinoma with bile duct tumor thrombus:surgical outcomes and the prognostic impact of concomitant major vascular invasion. World J Surg,2015,39(2):1485-1493. [20] Yoshizawa T,Toyoki Y,Hirai H et al. Invasive micropapillary carcinoma of the extrahepatic bile duct and its malignant potential. Oncol Rep,2014,32(4):1355-1361. [21] 殷晓煜,刘鑫,陈伟,等. 肝门部胆管癌手术切除的远期疗效及预后因素分析. 中华消化外科杂志,2016,15(4):329-333. [22] 周少君,黄志勇. 肝内胆管癌根治性切除术后肿瘤复发转移的预后因素分析. 中国普通外科杂志,2014,23(8):1024-1029. [23] 蔡文科,张永杰,卢军华,等. 术前血清CA19-9是肝门部胆管癌根治术患者预后的独立影响因素. 第二军医大学学报,2013,34(12):1333-1339. [24] 金昌国,张利刚,欧阳才国,等. 49例肝门部胆管癌的手术治疗分析. 军事医学,2012,36(1):60-64. [25] 余漪,周福平,郭玲玲,等. 术后肝功能指标对肝内胆管癌根治性切除患者预后的影响. 第二军医大学学报,2015,36(6):627-633. |